Concert Pharmaceuticals Inc. (CNCE)

10.88
0.12 1.09
NASDAQ : Health Technology
Prev Close 11.00
Open 11.05
Day Low/High 10.73 / 11.15
52 Wk Low/High 9.21 / 17.83
Volume 76.17K
Avg Volume 154.10K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 263.94M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATNI, CNCE, JTPY, KS Downgrades: DGICB, HELE, RLGY Initiations: GDP, POLA, SNES Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Announces The Appointment Of Marc Becker As Chief Financial Officer

Concert Pharmaceuticals Announces The Appointment Of Marc Becker As Chief Financial Officer

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018.

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017.

CNCE Crosses Above Average Analyst Target

CNCE Crosses Above Average Analyst Target

In recent trading, shares of Concert Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $24.67, changing hands for $24.86/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017.

Concert Pharmaceuticals Announces Completion Of Enrollment In First Cohort Of CTP-543 Phase 2a Trial

Concert Pharmaceuticals Announces Completion Of Enrollment In First Cohort Of CTP-543 Phase 2a Trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543.

Concert Pharmaceuticals To Report Third Quarter 2017 Financial Results On November 9, 2017, And Participate At Upcoming Investor Conferences

Concert Pharmaceuticals To Report Third Quarter 2017 Financial Results On November 9, 2017, And Participate At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.

Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent

Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 19.5% Annualized Using Options

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 19.5% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc shares, but cautious about paying the going market price of $14.65/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $12.50 strike, which has a bid at the time of this writing of 85 cents.

Concert Pharmaceuticals Announces Webcast At Wells Fargo Healthcare Conference

Concert Pharmaceuticals Announces Webcast At Wells Fargo Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Wells Fargo 2017 Healthcare Conference on Thursday, September 7, 2017, at 11:10 a.

Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2017.

Concert Pharmaceuticals To Report Second Quarter 2017 Financial Results On August 8, 2017

Concert Pharmaceuticals To Report Second Quarter 2017 Financial Results On August 8, 2017

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017, before the U.

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Termination Of The HSR Act Waiting Period For CTP-656 Asset Purchase Agreement With Vertex

Concert Pharmaceuticals Announces Termination Of The HSR Act Waiting Period For CTP-656 Asset Purchase Agreement With Vertex

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.

FDA Lifts Clinical Hold On Concert Pharmaceuticals Clinical Trial With CTP-543

FDA Lifts Clinical Hold On Concert Pharmaceuticals Clinical Trial With CTP-543

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the U.

Concert Pharmaceuticals Announces $30 Million Venture Debt Financing From Hercules Capital

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a $30.

Commit To Buy Concert Pharmaceuticals At $10, Earn 17% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc shares, but tentative about paying the going market price of $13.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $10 strike, which has a bid at the time of this writing of $1.05.

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 6, 2017, at 10:30 a.

Concert Pharmaceuticals Announces Departure Of Chief Financial Officer, Ryan Daws

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Ryan Daws, Chief Financial Officer, will be leaving the company in early June 2017 to return to investment banking.

Concert Pharmaceuticals Announces Shareholder Approval Of CTP-656 Asset Purchase Agreement With Vertex Pharmaceuticals

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that in connection with its annual shareholder meeting, Concert shareholders voted to approve the asset purchase agreement under which Vertex...

Vertex Undergoes FTC Scrubbing for Deal on CF Treatment

Vertex Undergoes FTC Scrubbing for Deal on CF Treatment

The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.

Concert Pharmaceuticals Receives Second Request From FTC Under HSR Act

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information ("Second Request") from the United States Federal Trade Commission (FTC) in connection with the...

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Concert must submit toxicology data to the FDA before proceeding with Phase 2 trials.

Concert Pharmaceuticals Announces Clinical Hold On CTP-543 Phase 2a Trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports First Quarter 2017 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2017.

Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial In Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the...

TheStreet Quant Rating: D (Sell)